Targeting PI3Kg to Reverse Immune Suppression in Lung Cancer

Novel Approaches and New Therapeutic Platforms

Immunotherapies and Personalized Vaccines

Judith Varner (UCSD)

Mark Onaitis (UCSD)

Sandip Patel (UCSD)

Lung cancer is a leading cause of death worldwide and there is a pressing need for new treatments that can cure the disease and promote long- term survival. The aim of this project is to investigate the effectiveness of Eganelisib, a first-in-class, immuno-oncology drug, in combination with standard-of-care chemotherapy and immune therapies in lab models.

We predict that this project will directly inform the development of new treatments for lung cancer and has the potential to improve the survival rates and quality of life for those affected by this devastating disease.

“Curebound funding helps to foster innovative cancer discoveries for the benefit of patients during a time in which other funding sources have become increasingly limited and directed towards lower academic risk, but lower- reward, initiatives. Curebound’s focus on transformative science with an eye to rapidly bringing these discoveries to the clinic to benefit patients helps bridge the grant divide and ensures that we continue to be leaders in biomedical innovation to help our cancer patients.” - Sandip Patel, MD, PhD